Obuprazine Phase IIb Signal Is Real but Mechanism-Blind, China-Bound, and One Phase Short

Obuprazine Phase IIb Trial Achieves Primary Endpoint in Schizophrenia

Tortugas Neuroscience and its partner Hansoh Pharma announced positive results from their Phase IIb clinical trial of obuprazine (TRTL-107) for acute schizophrenia. The double-blind, randomised study, conducted in China with 363 adult patients, successfully met its primary endpoint. All three obuprazine dose arms demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores compared to placebo at Day 42. The 1.5–3.0mg cohort showed the most significant improvement, with a placebo-adjusted difference of -16.7 points. The drug also exhibited numerically greater efficacy than aripiprazole and was well-tolerated.

• Obuprazine achieved statistically significant reductions in PANSS total scores across all three tested daily dose arms (1.5–3.0mg, 4.5–6.0mg, and 6.0–9.0mg) compared to placebo by Day 42. The lowest dose cohort (1.5–3.0mg) demonstrated the largest reduction, with a least-squares mean drop of 28.6 points from baseline, resulting in a placebo-adjusted difference of -16.7 points, highlighting its potent therapeutic effect.
• The trial data indicated that obuprazine demonstrated numerically greater efficacy than aripiprazole, a standard treatment, across several measures, including the primary endpoint. Furthermore, by Day 42, each obuprazine arm showed statistically significant improvements over placebo in PANSS positive symptom, negative symptom, and Marder cognitive factor scores, suggesting a comprehensive impact on schizophrenia symptoms.
• Obuprazine was well-tolerated, with low discontinuation rates of approximately 2.1% among treated patients, comparable to 2.5% for placebo. Following these compelling results, Tortugas Neuroscience plans to file an Investigational New Drug (IND) application in the US and will submit the complete trial findings for publication in a peer-reviewed journal, advancing the program towards further development.

Obuprazine's Compelling Efficacy and Safety in Acute Schizophrenia

Recent clinical trials have advanced the evidence base for several interventions in acute schizophrenia, spanning novel mechanisms, long-acting injectables, and dose-optimization strategies. The studies below highlight key efficacy and safety findings across distinct therapeutic approaches.

• EMERGENT-5 (Xanomeline and Trospium Chloride / KarXT): This 52-week open-label trial (NCT04820309) enrolled 566 psychiatrically stable adults with schizophrenia across 54 US sites. KarXT improved PANSS total, PANSS positive and negative subscale, and CGI-S scores over the trial duration. A total of 466/566 (82.3%) participants experienced ≥1 treatment-emergent adverse event (TEAE), the majority mild or moderate in intensity; severe TEAEs were reported in 33/566 (5.8%) participants. The most common TEAEs (≥5%) were nausea (23.1%), vomiting (20.3%), constipation (18.0%), hypertension (10.4%), diarrhea and dry mouth (9.4% each), dizziness (8.8%), headache (8.1%), dyspepsia (7.2%), somnolence (6.2%), weight decreased (5.7%), and hyperhidrosis (5.1%). No new safety issues emerged.

• Aripiprazole Lauroxil Trial (NCT01469039): This international, multicenter, randomized, double-blind, placebo-controlled trial evaluated aripiprazole lauroxil 441 mg and 882 mg administered as gluteal intramuscular injections once monthly for 12 weeks in 623 patients aged 18–70 with acute exacerbation of schizophrenia. PANSS total score improved significantly from baseline to day 85, with placebo-adjusted differences of -10.9 ± 1.8 (P < .001) for the 441 mg dose and -11.9 ± 1.8 (P < .001) for the 882 mg dose. Significant improvements were demonstrated as early as day 8. The proportion of patients rated very much or much improved on the CGI-I was significantly greater with both active doses versus placebo (P < .001). The most common treatment-emergent adverse events were insomnia, akathisia, headache, and anxiety; injection site reactions were predominantly injection site pain and were low in incidence.

• Lurasidone Dose Escalation Study (NCT01821378): This randomized, double-blind, placebo-controlled study assessed dose escalation in hospitalized adults with acute schizophrenia who were early nonresponders to lurasidone 80 mg/day (defined as PANSS score decrease < 20% at 2 weeks). In nonresponders to lurasidone 80 mg/day (n = 95), dose increase to 160 mg/day at week 2 significantly reduced PANSS total score at week 6 compared with continuing 80 mg/day (-16.6 vs -8.9; P < .05; effect size = 0.52). CGI-S improvement from week 2 to week 6 favored 160 mg/day over 80 mg/day (-1.0 vs -0.6; effect size = 0.44), though the difference was not statistically significant (P = .052). Lurasidone 20 mg/day did not demonstrate significant improvement versus placebo at week 6 in PANSS total (-17.6 vs -14.5; P = .26) or CGI-S (-0.93 vs -0.73; P = .17) scores. Few dose-related adverse effects were observed.

Designing the Phase IIb Trial for Obuprazine in Schizophrenia

Several pivotal randomized controlled trials in acute schizophrenia share a common methodological framework, employing double-blind, placebo-controlled designs with PANSS total score as the primary efficacy endpoint and CGI-S as a key secondary measure. Trial durations range from 4 to 13 weeks, with flexible or fixed dosing strategies and safety assessments including EPS rating scales.

Obuprazine's Phase IIb: A New Horizon for Schizophrenia Treatment

The recent announcement from Tortugas Neuroscience and Hansoh Pharma regarding positive Phase IIb results for obuprazine (TRTL-107) in acute schizophrenia marks a potentially significant step forward in a therapeutic area desperately seeking innovation. Schizophrenia treatment is often a delicate balance between symptom control and managing burdensome side effects that can severely impact patient quality of life and adherence. Existing atypical antipsychotics, while effective, frequently come with trade-offs. For instance, drugs like olanzapine are associated with metabolic issues and weight gain, while others such as iloperidone can prolong the QTc interval and cause orthostatic hypotension. Even aripiprazole, known for its relatively favorable extrapyramidal symptom profile, can still present challenges.

Obuprazine's ability to achieve statistically significant reductions in PANSS total scores, coupled with a report of being well-tolerated and showing numerically greater efficacy than aripiprazole, suggests a promising profile. This could mean a new option that not only effectively manages acute psychotic symptoms but also minimizes the adverse events that often lead to treatment discontinuation. The prospect of a well-tolerated antipsychotic is particularly compelling, as it directly addresses a critical unmet need for therapies that improve long-term patient outcomes through enhanced adherence.

However, it is crucial to approach these early-stage results with appropriate caution. While encouraging, Phase IIb data must be robustly confirmed in larger, longer Phase III trials. The 'numerically greater' efficacy over aripiprazole, while positive, is not a claim of statistical superiority and will require rigorous head-to-head comparisons. Furthermore, the full long-term safety profile, including potential metabolic, cardiovascular, or extrapyramidal effects, needs comprehensive evaluation over extended treatment durations. The trial's focus in China also highlights the need for broader studies to confirm generalizability across diverse patient populations. Should obuprazine continue to demonstrate this favorable balance of efficacy and tolerability in subsequent trials, it could indeed offer a meaningful improvement in the standard of care for acute schizophrenia.